Rontalizumab

Rontalizumab is a humanized monoclonal antibody^[1] being developed by Genentech.^[2] As of November 2009^[update], it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.^[3]

References[edit]

^ WHO Drug Information
^ Genentech: Rontalizumab (rhuMAb IFN alpha)
^ Clinical trial number NCT00962832 for "A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)" at ClinicalTrials.gov

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.